From a therapeutics perspective, gene therapy with TP53 (rAd-p53, Ad5CMV-p53), and antidiabetic medication metformin, which indirectly activates STK11/AMPK activity51, are currently being evaluated under multiple clinical trials for various cancer types (source: ClinicalTrials.gov). This evidence concerns the gene PRKAA1 and cancer.